Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

Recruiting
18 years or above
All
Phase N/A
110 participants needed
1 Location

Study Overview

This is a multi-center, hospital based, cross-sectional study based on data from patient medical records, including laboratory results. The study will include adult patients with chronic (> 1 year duration) primary Immune Thrombocytopenia (ITP) only. Patients will be identified based on a laboratory confirmed diagnosis of ITP in the medical records, where there is also a physician-confirmed diagnosis of primary ITP. If patients consent to take part in the study, a routine clinical visit will also serve as the study visit. Patients who do not have a routine visit scheduled during the study period but who would otherwise be eligible may be contacted by the site. In such cases, clinicians may use their discretion to schedule a visit specifically for study purposes.

All study participants will have a routine blood test as part of their standard clinical care at the study visit, and this same procedure will be used to collect supplementary blood samples to assess a variety of biomarkers.

Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Immune Thrombocytopenia, Primary Immune Thrombocytopenia, Adult Immune Thrombocytopenia
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • Patient diagnosed with chronic (ITP with > 1 year duration) primary ITP living in the USA or the UK:
    • On ITP pharmacologic treatment, , including on-demand treatment strategy, regardless of last platelet count (below or above 100 x 10^9 counts/L);
    • Patients with their most recent platelet count >50 x 109 counts/L) and without any ITP-specific treatment for 1 year or less.
  • Adult patient who are 18 years or older at index date
  • Patient who has received at least one initial first line ITP therapy (CS/ IVIg/ANTI d) with initial response as of index date and indicated by one of the following:
    • Platelet count ≥ 50 x 10^9 counts /L; OR
    • Platelet count ≥ 30 x 10^9 counts /L with at least a two-fold increase from baseline within 1 month since start of treatment, as per ASH 2019 guidelines; OR
    • A medical record of initial response as determined by clinical judgement, considering documented platelet count along with overall patient condition and relevant medical factors.
  • Patients whose medical history related to the study objectives are available from

    the site covering 12 months prior to index date.

  • Patient provided informed consent to participate in the study.

Exclusion Criteria:

  • Secondary ITP.
  • Patients with their most recent platelet count >50 x 10^9 counts/L and without any ITP-specific treatment for more than 1 year.
  • Patients with recent or active infection recorded 14 days or less before index date; patients with uncontrolled chronic infections or who were recently diagnosed with a chronic infection (≤14 days of index date).
  • Patients with vaccination in 28 days before index date.
  • Patients treated with rilzabrutinib on or before index date.
  • Patients who participated in an interventional clinical trial for any investigational drug in the 180 days prior to index date.

Updated on 07 Nov 2025. Study ID: NCT06665308

Find a study site near you

Your contact details have been shared with the study team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language